Pfizer’s Debt Concerns Cast Doubt on Viking Therapeutics Acquisition

**Novo Nordisk and Eli Lilly Lead in the Weight Loss Market as Viking Therapeutics Emerges a Potential Game-Changer

In the burgeoning pharmaceutical landscape, the spotlight intensely focuses on weight loss treatments, a segment currently dominated by industry behemoths Novo Nordisk and Eli Lilly. These companies have significantly capitalized on the therapeutic potential of semaglutide and tirzepatide, propelling medications such as Ozempic, Wegovy, and Mounjaro to blockbuster status. The race, however, might soon include a new contender, Viking Therapeutics, following its promising phase 2 trial results for the obesity drug candidate VK273.